Corning Jerry Pharmaceutical-B (09966) is now up nearly 5%. As of press release, it has risen 4.67% to HK$4.48, with a turnover of HK$11.091 million.
The Zhitong Finance App learned that Corning Jerry Pharmaceutical-B (09966) is now up nearly 5%. As of press release, it has risen 4.67% to HK$4.48, with a turnover of HK$11.091 million.
According to the news, Corning Jerry Pharmaceuticals announced that the results of a phase II clinical study of PD-L1/CTLA-4 dual-antibody KN046 combined with albumin-binding paclitaxel for first-line treatment of advanced triple-negative breast cancer were recently published online in the internationally renowned journal Nature Communications. The results showed that first-line treatment of tri-negative breast cancer with KN046 combined with albumin conjugated paclitaxel showed encouraging progression-free survival (PFS) and overall survival (OS) benefits, and was well tolerated and safe to control.
Notably, Corning Jerry Biopharmaceuticals and 3D Medicine previously announced that they have entered into a licensing agreement with Indian-listed pharmaceutical company Glenmark to grant Glenmark an exclusive license and sub-license for kN035 (Envolimab injection, trade name: Envida) for oncology indications to develop KN035 in India and the Asia-Pacific region (excluding Singapore, Thailand, and Malaysia), the Middle East and Africa, Russia, the CIS and Latin America to commercialize KN035 in all areas of oncology use.